Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis
T Gomes, D McCormack, SA Kitchen… - … Open Access Journal, 2021 - cmajopen.ca
Background: Several Canadian provinces have introduced reimbursement policies
mandating substitution of innovator biologics with lower-cost biosimilars. We estimated the …
mandating substitution of innovator biologics with lower-cost biosimilars. We estimated the …
[HTML][HTML] Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada
Methods We conducted a retrospective, cross-sectional study of all DAAs dispensed to
outpatients in Canadian provinces between September 1, 2017 and August 31, 2018 using …
outpatients in Canadian provinces between September 1, 2017 and August 31, 2018 using …
Characteristics of high–drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis
M Tadrous, D Martins, MM Mamdani… - … Association Open Access …, 2020 - cmajopen.ca
Background: Drugs are the fastest growing cost in the Canadian health care system, owing
to the increasing number of high-cost drugs. The objective of this study was to examine the …
to the increasing number of high-cost drugs. The objective of this study was to examine the …
Demographic characteristics and cost of treatment among oncology patients in a publicly funded system, the Ontario Trillium Drug Program: a retrospective cohort …
SY Cheng, FE Saxena, SJ Seung, CC Earle… - … Open Access Journal, 2019 - cmajopen.ca
Background: The aim of this study was to characterize the demographic characteristics and
investigate the cost of a publicly funded system, the Ontario Trillium Drug Program (TDP), for …
investigate the cost of a publicly funded system, the Ontario Trillium Drug Program (TDP), for …
Examining the registration for and unrealized benefits from BC's Fair PharmaCare Plan
CMY Chiu - 2022 - open.library.ubc.ca
Background: Fair PharmaCare is a catastrophic public drug plan which is available to all the
residents of British Columbia. Coverage is determined by income-based deductibles and …
residents of British Columbia. Coverage is determined by income-based deductibles and …
Utilization of Old-Versus New-Generation Biologics for Plaque Psoriasis for Public and Private Payers in Canada
P Dyrda, C Vannabouathong, K Peter… - … Journal of Health …, 2022 - canjhealthtechnol.ca
Executive Summary Background: Plaque psoriasis (PsO) is an immune-mediated skin
condition characterized by red, scaly, raised patches that frequently produce itching, pain …
condition characterized by red, scaly, raised patches that frequently produce itching, pain …
[HTML][HTML] CADTH Health Technology Review Utilization of Old-Versus New-Generation Biologics for Plaque Psoriasis for Public and Private Payers in Canada
P Dyrda, C Vannabouathong, K Peter, N Bansback… - canjhealthtechnol.ca
Issue: Recent health technology reviews by CADTH, including a national Environmental
Scan of biologics for PsO across public drug plans and a review of the clinical evidence on …
Scan of biologics for PsO across public drug plans and a review of the clinical evidence on …
[PDF][PDF] Confidential
TW Count - cmajopen.ca
BACKGROUND: Drugs are the fastest growing cost in the Canadian healthcare system, due
to the increased number of high-cost drugs. The objective of this study was to examine the …
to the increased number of high-cost drugs. The objective of this study was to examine the …